Compare BWLP & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BWLP | DFTX |
|---|---|---|
| Founded | 1935 | 2019 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | N/A | N/A |
| Metric | BWLP | DFTX |
|---|---|---|
| Price | $18.75 | $17.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $30.33 |
| AVG Volume (30 Days) | 278.5K | ★ 1.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.24% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.90 | N/A |
| P/E Ratio | $15.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.86 | $14.62 |
| 52 Week High | $18.35 | $18.70 |
| Indicator | BWLP | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 76.51 | 51.34 |
| Support Level | $11.79 | $16.31 |
| Resistance Level | N/A | $18.10 |
| Average True Range (ATR) | 0.38 | 0.96 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 100.00 | 66.52 |
BW LPG Ltd is an LPG shipping. It uses pioneering technology to power its vessels with cleaner-burning liquefied petroleum gas (LPG) and invest in R&D to take towards a zero-carbon future. The company is organized into two main segments: The shipping segment and the product services segment which buy and sell liquid petroleum gas and deliver it to customers. It generates the majority of its revenue from the shipping segment.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).